AC
FLNA

Aristides Capital’s Filana Therapeutics FLNA Stock Holding History

Aristides Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,800
Closed -$377K – 348
2024
Q3 		$377K Buy
+12,800
New +$295K 0.12% 117
2022
Q2 		– Sell
-30,400
Closed -$1.13M – 197
2022
Q1 		$1.13M Buy
+30,400
New +$1.29M 0.69% 41

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristides Capital's FLNA Position: Q3 2025 in Review

Aristides Capital sold out of Filana Therapeutics (FLNA) in Q3 2025, closing a stake of 16,092 shares — an estimated $29.1K sold.

Aristides Capital first reported a position in FLNA in Q4 2021 and held it in 7 quarters. The position peaked at $1.3M in Q4 2021. 103 funds tracked by Wall St. Rank hold FLNA as of Q3 2025.

  • Aristides Capital reported no remaining Filana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Aristides Capital sold 16,092 Filana Therapeutics shares in Q3 2025, an estimated $29.1K.
  • Aristides Capital first reported a position in Filana Therapeutics in Q4 2021 and held it in 7 quarters.
  • Aristides Capital's Filana Therapeutics position peaked at $1.3M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2025.

Based on Aristides Capital's 13F filing for Q3 2025, filed 13 Nov 2025.